Intensity Therapeutics — Third Quarter 2026 Earnings Summary

Intensity Therapeutics resumed new patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study during the third quarter of 2026 following previous pauses due to funding and protocol adjustments. Preliminary data from the first 14 patients in the INVINCIBLE-4 study showed a 71% pathological complete response rate for patients treated with INT230-6 prior to standard-of-care compared to 42% for standard-of-care alone. The company reported a net loss of $3.5 million for the quarter and held $8.5 million in cash and cash equivalents as of September 30, 2026. Additionally, the company raised $1.5 million in net proceeds from its at-the-market facility during the third quarter.